Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia

Despite major advances in the management and high cure rates of childhood acute lymphoblastic leukemia (ALL), patients still suffer from many drug-induced toxicities, sometimes necessitating dose reduction, or halting of cytotoxic drugs with a secondary risk of disease relapse. In addition, investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Maamari, Dimitri, El-Khoury, Habib, Saifi, Omran, Muwakkit, Samar A, Zgheib, Nathalie K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429230/
https://www.ncbi.nlm.nih.gov/pubmed/32848445
http://dx.doi.org/10.2147/PGPM.S239602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429230/
https://www.ncbi.nlm.nih.gov/pubmed/32848445
http://dx.doi.org/10.2147/PGPM.S239602

Ejemplares similares